Cargando…
2-Year Real-World Outcomes with Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: Literature Review and Meta-analysis of Patient-Relevant Outcomes
BACKGROUND: The 96 weeks’ assessment from the VIEW studies provided insights into the long-term efficacy of intravitreal aflibercept (IVT-AFL) in neovascular age-related macular degeneration (nAMD) and demonstrated that it was possible to maintain long-term outcomes while moving from a fixed bimonth...
Autores principales: | Carrasco, Joao, Daien, Vincent, Eldem, Bora M., Spoorendonk, Jelle A., Yoon, Jisu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319257/ https://www.ncbi.nlm.nih.gov/pubmed/34075564 http://dx.doi.org/10.1007/s40123-021-00350-5 |
Ejemplares similares
-
Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies
por: Carrasco, Joao, et al.
Publicado: (2019) -
Twenty-four-month real-world visual outcomes of intravitreal aflibercept as monotherapy for the treatment of neovascular age-related macular degeneration
por: Siempis, Thomas, et al.
Publicado: (2019) -
Real-World Outcomes of Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration: A Large-Scale Postmarketing Surveillance in Korea
por: Ryu, Gahyung, et al.
Publicado: (2021) -
Visual and Anatomical Outcomes of Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration
por: Gharbiya, Magda, et al.
Publicado: (2014) -
Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B, et al.
Publicado: (2022)